cell disorders presenting with systemic mast cell activation symptoms. 
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway Relapsed and refractory lymphoid and myeloid malignancies are often characterized by progressive resistance to standard chemotherapy as well as poor long-term outcomes. Additionally, many of the conventional treatment regimens may be accompanied by significant toxicity in this heavily pretreated population. Consequently, there is a need for novel therapies in these patients. Specific inhibition of essential signaling pathways offers potential for the design of rational therapeutic alternatives to cytotoxic chemotherapy. Among potential promising targets is casein kinase-2 (CK2), a highly conserved serine-threonine protein kinase comprised of two catalytic (a and a 0 ) and two regulatory (b) subunits. CK2 regulates a large number of critical signaling networks and downstream prosurvival and antiapoptotic substrates known to be essential to hematopoietic cell function. 1, 2 CK2 has been found to be overexpressed in many cancers, including hematologic malignancies such as chronic lymphocytic leukemia (CLL), 3 acute myeloid leukemia (AML), 4 T-cell acute lymphocytic leukemia (T-ALL) 5 and multiple myeloma. 6 Malignant cells are more dependent than normal tissues on upregulated levels of CK2 to sustain their growth and viability, 7 and elevated levels of CK2 have been found to correlate with inferior prognosis. 2 Consequently, despite its critical role in a diverse array of cellular processes, malignant cells are significantly more sensitive to CK2 downregulation; 2-9 potentially increasing its appeal as a therapeutic target.
CX-4945 is a selective, potent and orally bioavailable inhibitor of both isoforms of the CK2 catalytic subunits, and is the first smallmolecule inhibitor of CK2 to progress to human clinical trials. 9 Anti-tumor activity of CX-4945 has been validated in cancer cell lines and murine xenograft models, and biological activity has been observed in early phase clinical trials treating solid tumors. [9] [10] [11] However, little is known about its activity in leukemias and lymphomas. Therefore, using primary patient samples, we explored the therapeutic potential of CX-4945 across a wide spectrum of hematologic malignancies.
After informed consent, in accordance with the Declaration of Helsinki and approved by the institutional review board, Ficollpurified leukemia cells from 224 patients were cultured in the presence or absence of four serial dilutions of CX-4945 (Cylene Pharmaceuticals Inc., San Diego, CA, USA) ranging from 10 nM to 10 mM. Overall, 74 CLL, 60 AML, 58 B-cell acute lymphocytic leukemia, 13 chronic monomyelocytic leukemia (CMML), 4 T-ALL, 11 lymphoma and 4 chronic myeloid leukemia (CML) patients were included in the analysis. Purified leukemia cells were then cultured in RPMI þ 20% fetal bovine serum þ b-mercaptoethanol. A tetrazolium-based assay (MTS) was used to measure cell viability, which was then used to calculate IC 50 values.
Of the seven types of hematologic malignancies evaluated, all except CMML and CML demonstrated a subset of patients with significantly decreased viability (IC 50 o1 mM) in response to CX-4945 (Table 1 and Figure 1a ). Median IC 50 of all samples tested was 6.7 mM. CX-4945 appeared to be the most active in lymphoid malignancies, as this group contained the highest subset of sensitive patients (Table 1) . Of note, among the 16 sensitive CLL samples tested, 6 samples had an IC 50 o100 nm suggesting that there is a subset of samples that are highly sensitive to CK2 inhibition. Significant decreases in CLL cell viability in response to treatment with CX-4945 were observed in samples harboring a variety of high-risk features such as advanced Rai stage, CD38 and/or Zap 70 expression, unmutated variable region of the immunoglobulin heavy chain (IgV H ), chromosome 11q or17p Abbreviations: AML, acute myeloid leukemia; B-ALL, B-cell acute lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic monomyelocytic leukemia; CLL, chronic lymphocytic leukemia; T-ALL, T-cell acute lymphocytic leukemia. Median IC 50 of all samples tested was 6.7 mM.
Accepted article preview online 31 July 2013; advance online publication, 27 August 2013 deletion. No specific biologic factors, including IgV H mutational status, were found to correlate with sensitivity. Notably, three of nine (33.3%) samples with known 17p deletion exhibited sensitivity (IC 50 o1 mM) to CX-4945 with a median IC 50 of 409.2 nM. Given that CX-4945 appeared to be most active in lymphoid malignancies, specifically CLL, we subsequently focused on this population.
The prosurvival and chemoprotective roles of the bone marrow and lymph node microenvironment have been well described in CLL. 12 Therefore, we cultured purified CLL cells obtained from six CLL patients in HS-5 stromal cell-conditioned media (RPMI þ 10% fetal bovine serum plated over HS-5 cells for 3 h) to mimic the in-vivo CLL microenvironment, and found that CX-4945 decreased cell viability (Figure 1b) . This finding suggests that CX-4945 may be effective at reducing CLL cell viability not only in the peripheral blood, but also in protective compartments such as the bone marrow and lymph nodes.
B-cell receptor (BCR) activation leads to survival and proliferation of B-lymphocytes through signaling of survival kinases such as PI3K and AKT. Drugs that inhibit the transmission of signals through the BCR have been shown to disrupt the microenvironment and promote apoptosis. 13 Located downstream of the BCR, CK2 has an important role in the regulation of oncogenic pathways shared with the BCR, including PI3K and AKT, 1, 3, 7, 8 and also functions in the DNA repair response.
6,10 CK2 inhibition downregulates AKT activity and enhances the cytotoxic effect of chemotherapy. 3, 5, 6, [8] [9] [10] Specifically, early work using a CLL mouse model demonstrated that CX-4945 plus the purine nucleoside analog fludarabine was more effective than fludarabine alone.
14 Furthermore, given that cell survival relies on the convergence of many regulatory inputs including those transmitted via the BCR, we hypothesized that inhibiting the growth and survival pathway at more than one site would lead to enhanced activity. We therefore investigated the efficacy of CX-4945 in combination with fludarabine, which continues to form the backbone of cytotoxic CLL therapy, and with inhibitors of kinases known to be essential to the BCR pathway.
For synergy experiments, purified leukemia cells were resuspended in HS-5-conditioned media and added to wells containing serial dilutions of CX-4945 alone and in combination with serial dilutions of agents known to disrupt BCR-mediated signaling pathways, including the PI3K-delta isoform-specific inhibitor GS-1101 (Selleck Chemicals, Houston, TX, USA), the inhibitor of Bruton's tyrosine kinase ibrutinib (Selleck Chemicals, Houston, TX, USA) and fludarabine. Dilutions of all drugs ranged from 41.1 nM to 10 mM. Cells were cultured for 72 h and MTS was used to measure cell viability. Synergy analysis was performed using the Chou-Talalay method. 15 We observed synergy (defined as median combination index (CI) o1) between CX-4945 and GS-1101 in six of eight samples tested (Figure 1c In conclusion, these results demonstrate that the CK2-inhibitor CX-4945 has preclinical activity across a broad range of hematologic malignancies, most significantly in lymphoid malignancies. Additionally, CX-4945 appears to enhance the efficacy of inhibitors of the BCR pathway as well as fludarabine in primary CLL cells. Given the complexity of the intracellular signaling networks in hematologic malignancies, rational drug combinations that target multiple sites in the prosurvival pathway represent a promising strategy for the treatment of this population. As such, CX-4945 warrants further investigation in combination with chemotherapy and BCR pathway inhibitors.
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